+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4751849
  • Drug Pipelines
  • February 2019
  • Region: Global
  • 157 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Janssen
  • Johnson and Johnson
  • Merck
  • Pfizer
  • Pharmacyclics
  • MORE
‘Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hairy Cell Leukemia (HCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hairy Cell Leukemia (HCL) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Hairy Cell Leukemia (HCL) - Disease Understanding and Treatment Algorithm

Hairy Cell Leukemia (HCL) is a cancer of blood and bone marrow in which the bone marrow makes too many lymphocytes. This rare type of leukemia gets worse slowly or does not get worse at all. The disease is called hairy cell leukemia because the leukemia cells look "hairy" when viewed under a microscope. The World Health Organization (WHO) (2018) categorizes hairy cell leukemia as a mature B-cell neoplasm. It is called hairy cell leukemia because hair-like projections can be seen on the surface of the cancer cells when they are viewed under a microscope and the 2016 revision of the WHO classification of lymphoid neoplasms

In hairy cell leukemia, too many blood stem cells become lymphocytes. These lymphocytes are abnormal and do not become healthy white blood cells. They are also called leukemia cells. The leukemia cells can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. This may cause infection, anemia, and easy bleeding. Some of the leukemia cells may collect in the spleen and cause it to swell

The Hairy Cell Leukemia (HCL) market report gives a thorough understanding of the Hairy Cell Leukemia (HCL) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hairy Cell Leukemia (HCL) in the US, Europe, and Japan

Hairy Cell Leukemia (HCL) Epidemiology

The Hairy Cell Leukemia (HCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report is segmented by diagnosed incident population, symptom-specific diagnosed incident population of Hairy Cell Leukemia, gender-specific diagnosed incident population and age-specific diagnosed incident population of Hairy Cell Leukemia

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight

According to this research, the incident population of Hairy Cell Leukemia (HCL) was estimated to be 2,378 [7MM] in 2018. United States accounts for the highest HCL cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Hairy Cell Leukemia, followed France

Hairy Cell Leukemia (HCL) Drug Chapters

This segment of the Hairy Cell Leukemia (HCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

In the first-line setting for patients, Purine analogs are the mainstay of HCL therapy for physically fit and symptomatic HCL patients, conferring in most cases a longer overall survival (OS). The treatment is based on either cladribine (2-CdA) or Pentostatin (DCF). Among the 7 major markets, the United States is estimated to have the maximum market share of Hairy Cell Leukemia, followed by EU5 and Japan. There are only various therapies approved for the treatment of patients with Hairy Cell Leukemia in the United States that include Leustatin (Janssen); Nipent (Pfizer); Intron-A (Merck); Roferon-A (Roche) and Lumoxiti (AstraZeneca). Leustatin and Nipent are the purine anlaogs been approved as the first line of therapy for the treatment of Hairy Cell Leukemia. Lumoxiti (moxetumomab pasudotox-tdfk) developed by AstraZeneca is the first in class therapy approved for the treatment of Hairy Cell Leukemia. Detailed chapters for all of these drugs, along with the upcoming therapy i.e., Ibrutinib (Imbruvica) as well as another promising candidate Vemurafenib (Zelboraf, Roche) have been covered in the report

Hairy Cell Leukemia (HCL) Market Outlook

The Hairy Cell Leukemia (HCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

According to this research, the global market of Hairy Cell Leukemia (HCL) was estimated to be USD 48.12 million in 2018. The United States accounts for the largest market size of Hairy Cell Leukemia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, the effective management of Hairy Cell Leukemia mainly involves the usage of Purine Analogues (Cladribine and Pentostatin), Rituximab, and Interferon-alpha 2b. These therapies are used as either monotherapy or in combination as various lines of treatment

The dynamics of Hairy Cell Leukemia market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including Vemurafenib (Zelboraf; Roche), Ibrutinib (Imbruvica; Pharmacyclics) and Moxetumomab (Lumoxiti; AstraZeneca, the drug is launched in the US recently, but not in other markets)

Lumoxiti (Moxetumomab) became the first ever drug therapy to receive USFDA approval as a third line of treatment in September 2018. The drug is a first-in-class medicine for hairy cell leukaemia and marks first new treatment option for patients in over 20 years

Hairy Cell Leukemia (HCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions

The market size of Hairy Cell Leukemia (HCL) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration

Vemurafenib is being developed as the first line of therapy, while Ibrutinib is expected to enter the market as second line of therapy; Both the therapies are already launched in the market for the treatment of other respective indications

Overall, with the launch of new therapies in various line of treatment (LoT), it is estimated that these therapies shall gradually replace the market of traditional therapies that are presently being used as 1st LoT, 2nd LoT and 3rd LoT, in the coming years

Hairy Cell Leukemia (HCL) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Hairy Cell Leukemia (HCL) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Hairy Cell Leukemia (HCL) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Hairy Cell Leukemia (HCL) market
  • Organize sales and marketing efforts by identifying the best opportunities for Hairy Cell Leukemia (HCL) market
  • To understand the future market competition in the Hairy Cell Leukemia (HCL) market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Janssen
  • Johnson and Johnson
  • Merck
  • Pfizer
  • Pharmacyclics
  • MORE
1 Key Insights

2 Hairy Cell Leukemia Market Overview at a Glance
2.1 Market Share (%) Distribution of Hairy Cell Leukemia in 2017
2.2 Market Share (%) Distribution of Hairy Cell Leukemia in 2028

3 Disease Background and Overview
3.1 Introduction
3.2 Signs and Symptoms
3.3 Etiology
3.4 Staging and Risk Stratification
3.5 Biology of HCL
3.6 Pathogenesis
3.7 Diagnosis
3.7.1 NCCN Clinical Practice Guidelines in Oncology - Hairy Cell Leukemia, Version 2.2018
3.7.2 European Society for Medical Oncology (ESMO): Clinical Practice Guidelines - Hairy Cell Leukemia
3.7.3 Consensus guidelines for the diagnosis Classic Hairy Cell Leukemia

4 Epidemiology and Patient Population
4.1 Key Findings

5 7MM Total Incident Patient Population of Hairy Cell Leukemia

6 Country Wise-Epidemiology of Hairy Cell Leukemia
6.1 The United States
6.1.1 Assumptions and Rationale
6.1.2 Diagnosed Incident Cases of Hairy Cell Leukemia in the United States
6.1.3 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in the United States
6.1.4 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in the United States
6.1.5 Age Specific Incident Cases of Hairy Cell Leukemia in the United States
6.2 EU5
6.2.1 Assumptions and Rationale
6.3 Germany
6.3.1 Diagnosed Incident Cases of Hairy Cell Leukemia in Germany
6.3.2 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia Germany
6.3.3 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in Germany
6.3.4 Age Specific Incident Cases of Hairy Cell Leukemia in Germany
6.4 France
6.4.1 Diagnosed Incident Cases of Hairy Cell Leukemia in France
6.4.2 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in France
6.4.3 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in France
6.4.4 Age Specific Incident Cases of Hairy Cell Leukemia in France
6.5 Italy
6.5.1 Diagnosed Incident Cases of Hairy Cell Leukemia in Italy
6.5.2 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in Italy
6.5.3 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in Italy
6.5.4 Age Specific Incident Cases of Hairy Cell Leukemia in Italy
6.6 Spain
6.6.1 Diagnosed Incident Cases of Hairy Cell Leukemia in Spain
6.6.2 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in Spain
6.6.3 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in Spain
6.6.4 Age Specific Incident Cases of Hairy Cell Leukemia in Spain
6.7 The United Kingdom
6.7.1 Diagnosed Incident Cases of Hairy Cell Leukemia in the United Kingdom
6.7.2 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in the United Kingdom
6.7.3 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in the United Kingdom
6.7.4 Age Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom
6.8 Japan
6.8.1 Assumptions and Rationale
6.8.2 Diagnosed Incident Cases of Hairy Cell Leukemia in Japan
6.8.3 Symptom-Specific Diagnosed Incident cases of Hairy Cell Leukemia in Japan
6.8.4 Gender Specific Diagnosed Incident cases of Hairy Cell Leukemia in Japan
6.8.5 Age Specific Incident Cases of Hairy Cell Leukemia in Japan

7 Treatment and Management of Hairy Cell Leukemia
7.1 ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for Treatment
7.2 Consensus Guidelines for the management of patients with classic Hairy Cell Leukemia
7.3 NCCN Clinical Practice Guidelines Hairy Cell Leukemia, Version 2.2018
7.3.1 Treatment Options
7.3.2 Treatment Guidelines

8 Unmet Needs

9 Marketed Therapies
9.1 Lumoxiti: AstraZeneca
9.1.1 Drug Description
9.1.2 Regulatory Milestones
9.1.3 Other Developmental Activities
9.1.4 Safety and Efficacy
9.1.5 Product Profile
9.2 Leustatin: Janssen
9.2.1 Drug Description
9.2.2 Regulatory Milestones
9.2.3 Safety and Efficacy
9.2.4 Product Profile
9.3 Nipent: Pfizer
9.3.1 Product Description
9.3.2 Regulatory Milestones
9.3.3 Other Developmental Activities
9.3.4 Safety and Efficacy
9.3.5 Product Profile
9.4 Intron A: Merck
9.4.1 Product Description
9.4.2 Regulatory Milestones
9.4.3 Safety and Efficacy
9.4.4 Product Profile
9.5 Roferon A: Roche
9.5.1 Product Description
9.5.2 Regulatory Milestones
9.5.3 Safety and Efficacy
9.5.1 Product Profile
9.6 Off-label Therapies
9.7 Rituximab: Roche
9.7.1 Product Description
9.7.2 Other Development Activities
9.7.3 Clinical Development
9.7.4 Product Profile

10 Emerging Therapies
10.1 Key cross competition- Emerging Therapies
10.2 Ibrutinib: Johnson and Johnson/ Pharmacyclics
10.2.1 Product Description
10.2.2 Other Development Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Vemurafenib: Roche
10.3.1 Product Description
10.3.2 Other Development Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile

11 Hairy Cell Leukemia: 7 Major Market Analysis
11.1 Key Findings
11.2 Market Size of Hairy Cell Leukemia in 7MM
11.2.1 Market Size of Hairy Cell Leukemia by Line of Therapies

12 Market Outlook by Country

13 The United States: Market Outlook
13.1 United States Market Size
13.1.1 Total Market Size of Hairy Cell Leukemia
13.1.2 Market Size of Hairy Cell Leukemia by Line of Therapies

14 EU-5 Countries: Market Outlook
14.1 Germany
14.1.1 Total Market size of Hairy Cell Leukemia
14.1.2 Market Size of Hairy Cell Leukemia by Line of Therapies
14.2 France
14.2.1 Total Market Size of Hairy Cell Leukemia
14.2.2 Market Size of Hairy Cell Leukemia by Line of Therapies
14.3 Italy
14.3.1 Total Market Size of Hairy Cell Leukemia
14.3.2 Market Size of Hairy Cell Leukemia by Line of Therapies
14.4 Spain
14.4.1 Total Market Size of Hairy Cell Leukemia
14.4.2 Market Size of Hairy Cell Leukemia by Line of Therapies
14.5 United Kingdom
14.5.1 Total Market Size of Hairy Cell Leukemia
14.5.2 Market Size of Hairy Cell Leukemia by Therapies

15 Japan: Market Outlook
15.1.1 Total Market Size of Hairy Cell Leukemia
15.1.2 Market Size of Hairy Cell Leukemia by Therapies

16 Market Drivers

17 Market Barriers

18 Appendix
18.1 Report Methodology

19 Publisher Capabilities

20 Disclaimer

21 About the Publisher

List of Tables
Table 1: Genomic alterations in hairy cell leukemia (HCL), hairy cell leukemia-variant (HCL-V), splenic diffuse red pulp lymphoma (SDRPL) and splenic marginal zone lymphoma (SMZL)
Table 2: Differential diagnoses in HCL and their characteristic features.
Table 3: NCCN Categories of Evidence and Consensus
Table 4: Diagnostic workup of classical HCL
Table 5: Diagnostic criteria for HCL and HCL-V
Table 6: Initial workup for a patient suspected of hairy cell leukemia
Table 7: Incident Patient Population of Hairy Cell Leukemia in 7MM (2017-2028)
Table 8: Diagnosed Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Table 9: Symptom-Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Table 10: Gender Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Table 11: Age-Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Table 12: Diagnosed Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Table 13: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Table 14: Gender Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Table 15: Age-Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Table 16: Diagnosed Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Table 17: Symptom-Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Table 18: Gender Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Table 19: Age-Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Table 20: Diagnosed Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Table 21: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Table 22: Gender Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Table 23: Age-Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Table 24: Diagnosed Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Table 25: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Table 26: Gender Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Table 27: Age-Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Table 28: Diagnosed Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Table 29: Symptom-Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Table 30: Gender Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Table 31: Age-Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Table 32: Diagnosed Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Table 33: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Table 34: Gender Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Table 35: Age-Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Table 36: Definition of response categories
Table 37: Initial work-up for patient suspected of hairy cell leukemia
Table 38: Implications for Recommendations
Table 39: Assessment of response in HCL
Table 40: Assessment of response in HCL
Table 41: Supportive Care
Table 42: Lumoxiti, Clinical Trial Description, 2019
Table 43: Initial work-up for a patient suspected of hairy cell leukemia
Table 44: Rituximab Clinical Trial Description, 2019
Table 45: Key cross competition - Emerging Therapies
Table 46: Ibrutinib, Clinical Trial Description, 2018
Table 47: Vemurafenib, Clinical Trial Description, 2019
Table 48: 7 Major Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 49: 7 Major Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 50: United States Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 51: The US Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 52: Germany Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 53: Germany Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 54: France Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 55: France Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 56: Italy Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 57: Italy Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 58: Spain Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 59: Spain Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 60: United Kingdom Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 61: The UK Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Table 62: Japan Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Table 63: Market Size of Hairy Cell Leukemia by Therapies in USD Million (2017-2028)

List of Figures
Figure 1: Role of a-galactosidase A in GL-3 catabolism
Figure 2: RAF-MEK-ERK signaling pathway in hairy cell leukemia.
Figure 3: B-cell development in peripheral lymphoid organs: the germinal centre reaction
Figure 4: Signaling pathways involved in hairy-cell leukemia (HCL) growth
Figure 5: Hairy-cell leukemia (HCL) homing and dissemination properties
Figure 6: Bone-marrow fibrosis in hairy-cell leukemia (HCL)
Figure 7: ‘Hairy’ morphology: molecular mediators and their relationship with hairy-cell survival
Figure 8: Histologic image of a hairy cell
Figure 9: Incident Patient Population of Hairy Cell Leukemia in 7MM (2017-2028)
Figure 10: Diagnosed Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Figure 11: Symptom-Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Figure 12: Gender Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Figure 13: Age-Specific Incident Cases of Hairy Cell Leukemia in the United States (2017-2028)
Figure 14: Diagnosed Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Figure 15: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Figure 16: Gender Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Figure 17: Age-Specific Incident Cases of Hairy Cell Leukemia in Germany (2017-2028)
Figure 18: Diagnosed Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Figure 19: Symptom-Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Figure 20: Gender Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Figure 21: Age-Specific Incident Cases of Hairy Cell Leukemia in France (2017-2028)
Figure 22: Diagnosed Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Figure 23: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Figure 24: Gender Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Figure 25: Age-Specific Incident Cases of Hairy Cell Leukemia in Italy (2017-2028)
Figure 26: Diagnosed Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Figure 27: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Figure 28: Gender Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Figure 29: Age-Specific Incident Cases of Hairy Cell Leukemia in Spain (2017-2028)
Figure 30: Diagnosed Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Figure 31: Symptom-Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Figure 32: Gender Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Figure 33: Age-Specific Incident Cases of Hairy Cell Leukemia in the United Kingdom (2017-2028)
Figure 34: Diagnosed Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Figure 35: Symptom-Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Figure 36: Gender Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Figure 37: Age-Specific Incident Cases of Hairy Cell Leukemia in Japan (2017-2028)
Figure 38: Treatment algorithm for relapsed and refractory classical HCL according to ESMO guidelines
Figure 39: Treatment algorithm according to ESMO guidelines
Figure 40: Treatment algorithm according to ESMO guidelines
Figure 41: NCCN Treatment Guidelines
Figure 42: Unmet Needs of Hairy Cell Leukemia
Figure 43: 7 Major Market Size of Hairy Cell Leukemia in USD Million (2017-2028)
Figure 44: 7 Major Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 45: Market Size of Hairy Cell Leukemia in the United States, USD Million (2017-2028)
Figure 46: The US Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 47: Market Size of Hairy Cell Leukemia in Germany, USD Million (2017-2028)
Figure 48: Germany Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 49: Market Size of Hairy Cell Leukemia in France USD Million (2017-2028)
Figure 50: France Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 51: Market Size of Hairy Cell Leukemia in Italy, USD Million (2017-2028)
Figure 52: Italy Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 53: Market Size of Hairy Cell Leukemia in Spain, USD Million (2017-2028)
Figure 54: Spain Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 55: Market Size of Hairy Cell Leukemia in the United Kingdom, USD Million (2017-2028)
Figure 56: The UK Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 57: Market Size of Hairy Cell Leukemia in Japan, USD Million (2017-2028)
Figure 58: Market Size of Hairy Cell Leukemia by Line of Therapies in USD Million (2017-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca
  • Janssen
  • Pfizer
  • Merck
  • Roche
  • Johnson and Johnson
  • Pharmacyclics
Note: Product cover images may vary from those shown
Adroll
adroll